De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".

Creators: Clavio M; Cruciani F; Minetto P; Guolo F; Ballerini F; Marani C; De Astis E; Aquino S; Bergamaschi M; Mitscheunig L; Grasso R; Colombo N; Ghiggi C; Lovera D; Pastori G; Avenoso D; MIGLINO, MAURIZIO; GOBBI, MARCO

Others:: Clavio, M; Cruciani, F; Minetto, P; Guolo, F; Ballerini, F; Marani, C; De Astis, E; Aquino, S; Bergamaschi, M; Mitscheunig, L; Grasso, R; Colombo, N; Ghiggi, C; Lovera, D; Pastori, G; Avenoso, D; Miglino, Maurizio; Gobbi, Marco

Additional details